歐康維視生物-B：二零二三年年報

Futu NewsApr 25 17:05 · Announcements

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug

Ocumension Therapeutics' (HKG:1477) new drug for treating postoperative inflammation successfully achieved the expected results in a phase III clinical trial, according to a Monday filing with the Hon

MT NewswiresApr 15 14:47

Okanvision Bio-B (01477.HK): Phase III clinical trial of OT-502 in China reached the main end

Gelonghui, April 15 | Okanvision Bio-B (01477.HK) announced that OT-502 (DEXYCU, dexamethasone implant), a new drug for treating post-operative inflammatory indications, has successfully reached the expected main efficacy endpoint of its phase III clinical trial. That is, on day 8, the proportion of subjects with anterior atrial atrial cell clearance (ACC grade 0) in the treatment group with dexamethasone implants was significantly higher than in the placebo group, proving that this product is safe and effective in controlling inflammation after cataract surgery. The company expects to submit an OT-502 new drug application to the Drug Evaluation Center of the China National Drug Administration in the near future. O

Gelonghui FinanceApr 15 12:11

Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon

Ocumension Therapeutics (HKG:1477) said its new drug completed clinical phase III and will soon apply for a new drug registration, according to a Monday filing on the Hong Kong bourse. The drug, OT-70

MT NewswiresApr 8 14:39

Okanvision Bio-B (01477.HK): OT-702 phase III clinical trial completed in China

Gelonghui, April 8 | Okanvision Bio-B (01477.HK) announced that the phase III clinical trial of OT-702 (abercip intraocular injection solution, EYLEA biosimilar) has been successfully completed in China. OT-702 was jointly developed by the Group and its partner Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech”) (the company's shares are listed on the Hong Kong Stock Exchange Limited (stock code: 6955)). The phase III clinical study of OT-702 was carried out in cooperation between the two parties. The application for the new drug will be reviewed by the China Drug Administration in the near future

Gelonghui FinanceApr 8 12:03

Okanvision Bio-B (01477.HK): 2023 results meet expectations and expect recent R&D milestones

The 2023 revenue is in line with our expectations. The company announced its 2023 results: revenue of 246 million yuan, up 55.0% year on year; net loss to mother of 380 million yuan, which is narrower than last year, in line with our expectations. Trending products

中金公司Mar 25 16:46